Novartis takes on Regeneron, Roche blockbusters with Beovu approval

Look out, Regeneron and Roche. Novartis has the FDA go-ahead for its next blockbuster launch in Beovu, a drug for wet age-related macular degeneration (AMD) that beat out Regeneron's big-selling Eylea on some measures in a head-to-head trial. Novartis' Beovu won FDA approval Tuesday to treat wet AMD, a condition expected to affect 1.75 million people in the U.S. next year. In addition to Eylea, the med threatens Roche's Lucentis, which Novartis itself markets in Europe. That drug loses European patent protection in 2020, so Novartis expects to launch Beovu in Europe as Lucentis faces copycats there.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001265 seconds